First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with

EGFR mutation Leptomeningeal metastasis Lung adenocarcinoma Osimertinib

Journal

International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 05 07 2020
accepted: 04 10 2020
entrez: 25 1 2021
pubmed: 26 1 2021
medline: 26 1 2021
Statut: epublish

Résumé

Leptomeningeal metastasis (LM) from lung cancer has poor prognosis, and effective therapy has not been established. We present the case of a 54-year-old man with LM from lung adenocarcinoma harboring

Identifiants

pubmed: 33489707
doi: 10.1007/s13691-020-00453-z
pii: 453
pmc: PMC7797384
doi:

Types de publication

Case Reports

Langues

eng

Pagination

78-82

Informations de copyright

© The Japan Society of Clinical Oncology 2020.

Déclaration de conflit d'intérêts

Conflict of interestThe authors declare no conflicts of interest in relation to this article.

Références

Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
J Thorac Oncol. 2020 Apr;15(4):637-648
pubmed: 31887431
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
ESMO Open. 2017 Mar 7;2(Suppl 1):e000104
pubmed: 28848674
J Clin Oncol. 2020 Feb 20;38(6):538-547
pubmed: 31809241
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Thorac Cancer. 2020 Feb;11(2):436-442
pubmed: 31910497
J Thorac Oncol. 2015 Dec;10(12):1754-61
pubmed: 26334749
Lung Cancer. 2012 Jul;77(1):134-9
pubmed: 22487432
J Thorac Oncol. 2012 Apr;7(4):770-1
pubmed: 22425931
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
J Thorac Oncol. 2016 Nov;11(11):1962-1969
pubmed: 27539328
Case Rep Oncol. 2017 Sep 20;10(3):840-845
pubmed: 29070999
Oncotarget. 2016 Jan 26;7(4):3847-56
pubmed: 26716903
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Br J Cancer. 2018 Jan;118(1):32-37
pubmed: 29190637
Respirol Case Rep. 2017 May 02;5(4):e00241
pubmed: 28469919
Chin Clin Oncol. 2019 Jun;8(3):29
pubmed: 30943730
Lung Cancer. 2017 Dec;114:68-69
pubmed: 29173769

Auteurs

Yuki Ono (Y)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Kazuki Takada (K)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Atsushi Osoegawa (A)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Fumihiko Kinoshita (F)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Taro Oba (T)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Shuichi Tsukamoto (S)

Department of Thoracic Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan.

Tetsuzo Tagawa (T)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Yoshinao Oda (Y)

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Masaki Mori (M)

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.

Classifications MeSH